Metabolic syndrome and the older male population

Aging Male

Volumn 10, Issue 1, 2007, Pages 3-8

  Mazza, Angela D ^a   Morley, John E ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adiponectin; Diabetes; Insulin resistance; Leptin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; BIGUANIDE; METFORMIN; OMEGA 3 FATTY ACID; PLACEBO; RIMONABANT;

AGING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DEPRESSION; DIABETES CONTROL; DYSLIPIDEMIA; EDITORIAL; HUMAN; HYPERTENSION; HYPOGONADISM; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LIFESTYLE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL;

AGED; HUMANS; HYPOGONADISM; MALE; METABOLIC SYNDROME X; MIDDLE AGED; UNITED STATES;

EID: 33947302065     PISSN: 13685538     EISSN: 14730790     Source Type: Journal    
DOI: 10.1080/13685530701249592     Document Type: Editorial

References (63)

1. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52:1210-1214.
2. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
3. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
4. Alberti KG, Zimmer PZ. Definition, diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-553.
5. Athyros VG, Ganotakis ES, Elisaf M, Mikhailidis DP. The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr Med Res Opin 2005;21:1157-1159.
6. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Diabetes Care 2005;28:2289-2304.
7. Jackson RA. Mechanisms of age-related glucose intolerance. Diabetes Care 1990;13(Suppl 2):9-19.
8. Beck-Nielsen H, Groop LC. Metabolic and genetic characterization of prediabetic states. Sequence of events leading to non-insulin-dependent diabetes mellitus. J Clin Invest 1994;94:1714.
9. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005;365:1333.
10. Banks WA, Altmann J, Sapolsky RM, Phillips-Conroy JA, Morley JE. Serum leptin levels as a marker for a syndrome X-like condition in wild baboons. J Clin Endocrinol Metab 2003;88:1234-1240.
11. Jacob S, Machann J, Rett K, Brechtel K, Volk A, Renn W, Maerker E, Matthaei S, Schick F, Claussen CD, Haring HU. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring on type 2 diabetic subjects. Diabetes 1999;48:1113-1119.
12. Stefan N, Machann J, Schick F, Claussen CD, Thamer C, Fritsche A, Haring H. New imaging techniques of fat, muscle and liver within the context of determining insulin sensitivity. Hormone Research 2005;64(suppl 3);38-44.
13. Kim MJ, Rolland Y, Cepeda O, Gammack JK, Morley JE. Diabetes mellitus in older men. Aging Male 2006;9:139-147.
14. Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, DiPietro L, Cline GW, Shulman GI. Mitrochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003;300:1140-1142.
15. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548-2556.
16. Rolland YM, Perry HM III, Patrick P, Banks WA, Morley JE. Leptin and adiponectin levels in middle-aged postmenopausal women: association with lifestyle habits, hormones, and inflammatory markers - a cross-sectional study. Metabolism 2006;55:1630-1636.
17. Berg AH, Combs TP, Du X, Brownlee B, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001;7:947-953.
18. Combs TP, Wagner JA, Berger J, Doebber T, Wang W, Zhang BB, Tanen M, Berg AH, O'Rahilly S, Savage DB, Chatterjee K, Weiss S, Larson PJ, Gottesdiener KM, Gertz BJ, Charron MJ, Scherer PE, Moller DE. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARγ agonists: a potential mechanism of insulin sensitization. Endocrinology 2002;143:998-1007.
19. Travison TG, Morley JE, Araujo AB, O'Donnell AB, McKinlay JB. The relationship between libido and testosterone levels in aging men. J Clin Endocrinol Metab 2006;91:2509-2513.
20. Morley JE, Kaiser FE, Perry HM III, Patrick P, Morley PM, Stauber PM, Vellas B, Baumgartner RN, Garry PJ. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism 1997;46:410-413.
21. Kohn FM. Testosterone and body functions. Aging Male 2006;9:183-188.
22. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 2006;91:4335-4343.
23. Bojesen A, Kristensen K, Birkebaek NH, Fedder J, Mosekilde L, Bennett P, Laurberg P, Frystyk J, Flyvbjerg A, Christiansen JS, Gravholt CH. The metabolic syndrome is frequent in Klinefelter's syndrome and is associated with abdominal obesity and hypogonadism. Diabetes Care 2006;29:1591-1598.
24. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006;154:899-906.
25. Lee Ch, Kuo SW, Jung YJ, Hsieh CH, He CT, Yang TC, Lian WC, Chyi-Fan S, Pei D. The effect of testosterone supplementation on insulin sensitivity, glucose effectiveness, and acute insulin response after glucose load in male type 2 diabetics. Endocr Res 2005;31:139-148.
26. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448-4456.
27. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 2006;106:581-588.
28. Morley JE. Diabetes mellitus: a major disease of older persons. J Gerontol A Biol Sci Med Sci 2000;55:M255-M256.
29. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2006;29:59-42.
30. LeRoith D. Diabetes in the aging male. Aging Male 2005;8:133-134.
31. American Diabetes Association. Economic consequences of diabetes mellitus in the US in 2002. Diabetes Care 2003;26:917-932.
32. Rodriguez-Saldana J, Morley JE, Reynoso MT, Medina CA, Salazar P, Cruz E, Torres AL. Diabetes mellitus in a subgroup of older Mexicans: prevalence, association with cardiovascular risk factors, functional and cognitive impairment, and mortality. J Am Geriatr Soc 2002;50:111-116.
33. Miller DK, Lui LY, Perry HM III, Kaiser FE, Morley JE. Reported and measured physical functioning in older innercity diabetic African Americans. J Gerontol A Biol Sci Med Sci 1999;54:M230-M236.
34. Di Fazio I, Franzoni S, Frisoni GB, Gatti S, Cornali C, Stofler PM, Trabucchi M. Predictive role of single diseases and their combination on recovery of balance and gait in disabled elderly patients. J Am Med Dir Assoc 2006;7:208-211.
35. Johnson CL, Rifkind BM, Sempos CT, Carroll MD, Bachorik PS, Breifel RR, Gordon DJ, Burt VL, Brown CD, Lippel K, Cleeman JI. Declining serum total cholesterol levels among US adults: the National Health and Nutrition Examination Surveys. JAMA 1993;269:3002-3008.
36. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer H, Byrd-Holt DD. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: the Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998;21:518-524.
37. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
38. Saydah S. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes mellitus. JAMA 291;335-342.
39. Mooradian AD, Perryman K, Fitten J, Kavonian GD, Morley JE. Cortical function in elderly non-insulin dependent diabetic patients: behavioral and electrophysiologic studies. Arch Intern Med 1988;148:2369-2372.
40. Flood JF, Mooradian AD, Morley JE. Characteristics of learning and memory in streptozocin-induced diabetic mice. Diabetes 1990;39:1391-1398.
41. Yaffe K, Kanaya A, Lindquist K, Simonsick EM, Harris T, Shorr RI, Tylavsky FA, Newman AB. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004;292:2237-2242.
42. Farr SA, Banks WA, Morley JE. Effects of leptin on memory processing. Peptides 2006;27:1420-1425.
43. Banks WA, Coon AB, Robinson SM, Moinuddin A, Shultz JM, Nakaoke R, Morley JE. Triglycerides induce leptin resistance at the blood-brain barrier. Diabetes 2004;53:1253-1260.
44. Zarowitz BJ, Tangalos EG, Hollenack K, O'Shea T. The application of evidence-based principles of care in older persons (Issue 3): Management of diabetes mellitus. J Am Med Dir Assoc 2006;7:234-240.
45. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005;142:611-619.
46. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
47. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired gluocose tolerance. N Engl J Med 2001;344:1343-1350.
48. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537-544.
49. Kumar VB, Bernardo AE, Vyas K, Franko M, Farr S, Lakshmanan L, Buddhiraju C, Morley JE. Effect of metformin on nitric oxide synthase in genetically obese (ob/ob) mice. Life Sci 2001;69:2789-2799.
50. Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res 1998;6:47-53.
51. Diabetes Prevention Program Research Group; Crandall J, Schade D, Ma Y, Fujimoto WY, Barrett-Connor E, Fowler S, Dagogo-Jack S, Andres R. The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol A Biol Sci Med Sci 2006;61:1075-1081.
52. DeFillipis AP, Sperling LS. Understanding omega-3s. Am Heart J 2006;151:564-570.
53. Marchioli R, Barzi F, Bomba E, Chieffo C, DiGregorio D, DiMascio R, Franzosi MF, Geraci E, Levantesi G, Maggioni AP, Mantini L, Marfisi RM, Mastrogiuseppe G, Mininni N, Licolosi GL, Santini M, Schweiger C, Tavazzi L, Tognoni G, Tucci C, Valagussa F. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002;105:1897-1903.
54. Albert CM, Campos H, Stamper MJ, Ridker PM, Manson JE, Willett WC, Ma J. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Eng J Med 2000;346:1113-1118.
55. Rivellese A, Maffettone A, Iovine C, DiMarino L, Annuzzi G, Mancini M, Riccardi G. Long-term effects of fish oil on insulin resistance and plasma lipoproteins in NIDDM patients with hypertriglyceridemia. Diabetes Care 1996;19:1207-1211.
56. Montori VM, Farmer A, Wollan PC, Dinneen SE. Fish oil supplementation in type 2 diabetes. Diabetes Care 2000;23:1407-1415.
57. Friedberg C, Janssen MJ, Heine RJ, Grobbee DE. Fish oil and glycemic control in diabetes. Diabetes Care 1998;21:494-500.
58. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dincaag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Zinman B, Holman RR. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006;368:1096-1105.
59. Marfella R, D'Amico M, Di Filippo C, Siniscalchi A, Sasso FC, Portoghese M, Crescenzi B, Sangiuolo P, Nicoletti GF, Ferraraccio RR, Cacciapuoti F, Verza M, Coppola L, Paolisso G. Increased activity of the ubiquitin-proteasome system in patients with symptomatic carotid disease is associated with enhanced inflammation and may destabilize the atherosclerotic plaque: effects of rosiglitazone treatment. J Am Coll Cardiol 2006;47:2444-2455.
60. Cicero DG, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Ferrari I, Gravina A, Ragonesi PD. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial. Clin Ther 2006;28:679-688.
61. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-564.
62. Tangalos EG, Cota D, Fukioka K. Complex cardiometabolic risk factors: impact, assessment, and emerging therapies. J Am Med Dir Assoc 2006;7(7 Suppl):1-10.
63. Pi-Sunyer, FX, Aronne LJ, Hesmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. JAMA 2006;295:761-775.